Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lotus Eye Hospital & Institute Buyback Yield % Chart
BOM:532998 vs HCA, THC, DVA: Buyback Yield % Comparison
For the Medical Care Facilities subindustry, Lotus Eye Hospital & Institute's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lotus Eye Hospital & Institute Buyback Yield % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Lotus Eye Hospital & Institute's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Lotus Eye Hospital & Institute's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lotus Eye Hospital & Institute (BOM:532998) has a Buyback Yield % of 0.00 as of Aug. 08, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Lotus Eye Hospital & Institute and its competitors. According to the industry distribution chart, Lotus Eye Hospital & Institute ranks #999999 out of 269 companies in the Healthcare Providers & Services industry.
Is Lotus Eye Hospital & Institute's Buyback Yield % too high?
Lotus Eye Hospital & Institute's current Buyback Yield % is 0.00. Based on the distribution chart, Lotus Eye Hospital & Institute ranks #999999 out of 269 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Lotus Eye Hospital & Institute has a GF Score™ of 67/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Lotus Eye Hospital & Institute's Buyback Yield % compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Lotus Eye Hospital & Institute ranks #999999 out of 269 companies for Buyback Yield %. This places Lotus Eye Hospital & Institute in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Healthcare Providers & Services company?
A good Buyback Yield % depends on the Healthcare Providers & Services industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Lotus Eye Hospital & Institute and its competitors. Lotus Eye Hospital & Institute's current Buyback Yield % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lotus Eye Hospital & Institute stock overvalued right now?
Based on GuruFocus' analysis, Lotus Eye Hospital & Institute (BOM:532998) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹92.46, compared to a current price of ₹116.75 — trading 26.3% above its estimated fair value. The current Buyback Yield % is 0.00. Lotus Eye Hospital & Institute's overall GF Score™ is 67/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Lotus Eye Hospital & Institute (BOM:532998), the current Buyback Yield % is 0.00 as of Aug. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lotus Eye Hospital & Institute (BOM:532998) Overvalued in 2026?
Based on GuruFocus' analysis, Lotus Eye Hospital & Institute stock appears to be overvalued.
The current stock price of ₹116.75 is trading 26.3% above its estimated GF Value™ of ₹92.46.
GuruFocus considers Lotus Eye Hospital & Institute to be Modestly Overvalued.
Key valuation signals for BOM:532998:
Buyback Yield %: 0.00
GF Value™: ₹92.46 vs. price of ₹116.75 (26.3% above fair value)
No single metric tells the full story. See the BOM:532998 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lotus Eye Hospital & Institute Ltd is an India-based eye care hospital. It is engaged in providing treatment and care for eye diseases and disorders. It offers treatment services for eye conditions like refractive error, retina and uvea, cornea, glaucoma, pediatric, orbit and oculoplasty, neuro-ophthalmology, and binocular vision. In addition, the company also operates an eye bank for functioning eye donation activities. The company mainly operates in India and generates revenue by providing medical services, pharmacy sales, contact lenses, and optical, of which the majority of the revenue is derived from providing segmmedical services.
67GF Score
Get the complete analysis for BOM:532998
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:532998 has been successfully added to your 
